Here is what the page “Why Medicare Spending on Alzheimer’s Drugs Remains Lower Than Projected | Nova Global News” contains. Recent projections regarding Medicare Part B spending on new monoclonal antibody treatments for Alzheimer’s disease, such as lecanemab and donanemab, have... Recent projections regarding Medicare Part B spending on new monoclonal antibody treatments for Alzheimer’s disease, such as lecanemab and donanemab, have significantly overestimated the actual financial impact on the program. While initial reports warned of a potential fiscal crisis, the anticipated surge in expenditures has not materialized, resulting in a surprising budgetary relief for CMS.
This paradox is primarily attributed to the complex logistical hurdles and administrative friction inherent in the current healthcare delivery system rather than a lack of patient demand. Administering these high-maintenance therapies requires a robust, integrated clinical infrastructure that is currently fragmented, which has inadvertently acted as a bottleneck to widespread adoption. This listing links straight to the original page, where the content is available in full.